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Purpose: The role of arterial stenting in the treatment of femoral and popliteal arterial 
disease is controversial nd has been hampered by recommendations for patients to be 
given anticoagulants (oral warfarin) for several months or more. This study was 
undertaken toevaluate the immediate and midterm outcomes of vascular stents implanted 
percutaneously in the femoral nd popliteal arteries, without long-term anticoagulation. 
Methods: Over a 3-year period, 32 patients admitted to a vascular surgery service had 
arterial stents implanted in the femoral (n = 22) or popliteal (n -- 10) artery for the 
fol lo~ng indications: recurrent stenosis after angioplasty (n = 13), suboptimal result 
after angioplasty of occluded (n = 12) or calcified stenotic arteries (n = 2), percutaneous 
transluminal ngioplasty-induced thrombosis or dissection (n = 5). Access to the artery 
was gained by percutaneous insertion of a hemostatic sheath into the ipsilateral common 
femoral artery. Systemic heparin was given at the time ofstent insertion, and patients were 
prescribed aily low-dose aspirin. 
Results: Successful stent implantation was achieved in 31 of the 32 patients. Acute 
thrombosis ( < 30 days) occurred in two patients. There was no incidence of false aneurysm 
formation, acute leg ischemia, or vessel perforation. All patients were monitored by 
Doppler scanning index and duplex scanning within 24 hours, and thereafter at 3- to 
6-month intervals. The mean ankle-brachial systolic pressure index improved from 0.60 
(before treatment) o 0.88 (3 to 6 months after stenting). Stent occlusion has occurred in 
six patients; two stents were successfully salvaged with urokinase infusion. In follow-up 
to date (range 3 to 33 months) the primary patency rate by life-table analysis was 75% at 
18 months, whereas the secondary patency rate was 89% at the same interval. Restenosis 
(> 50% lumen diameter) was detected by duplex ultrasonography in seven of 25 patent 
stents (28%) at a mean interval of 9.5 months (range 4 to 15 months); of these, four 
patients remained clinically symptom-free d spite the ultrasound findings. 
Conclusions: We conclude that vascular stents can be implanted into the femoropopliteal 
arteries with few complications and with acceptable early and intermediate patency rates, 
without he need for long-term anticoagulation. Restenosis not prevented by stents, and 
the main value of stenting at this site appears to be in salvaging acute complications of 
percutaneous transluminal a gioplasty, or to correct suboptimal results after recanaliza- 
tion of occluded arteries. (J VASC SURG 1995;21:270-81.) 
of 
From the Departments of Vascular Surgery and Interventional 
Radiology (Drs. Waugh andSachinwalla), Royal Prince Alfred 
Hospital, Camperdown, Sydney. 
Presented at the Forty-second Scientific Meeting of the Interna- 
tional Society for Cardiovascular Surgery, North American 
Chapter, Seattle, Wash., June 6, 1994. 
Reprint requests: Geoffrey H. White, FRACS, Department of 
Surgery, University of Sydney, NSW 2006. Australia. 
Copyright © 1995 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/95/$3.00 + 0 24/6/61306 
270 
Percutancous transluminal angioplasty (PTA) of 
the femoropoplitcal rtcries is an attractive, less- 
invasive management option for patients with symp- 
toms of focal stenotic lesions or short occlusions of 
these arteries. Initial "success rates" for femo- 
ropopliteal angioplasty are commonly reported to be 
in the range of 85% to 95% for stenotic lesions 
and 70% to 85% for rccanalization of short-length 
(<3 cm) occlusions in experienced hands) '2 The 
success rate for occlusions longer than 3 cm is usually 
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less than 50% and the long-term patency rates and 
clinical outcome for short and long lesions are limited 
by a relatively high incidence of restenosis (or 
occlusion) of the treated site? ,35 
Arterial restenosis at the site of prior PTA was a 
clear impetus for the development and initial clinical 
trials of arterial stents. Use of stents for "salvage" of 
complications such as intimal flap, dissection, and 
acute occlusion of the PTA site was a secondary 
benefit, and has proven particularly beneficial in 
coronary artery angioplasty. 6 
The role of vascular stents in the treatment of 
atherosclerotic disease in the iliac arteries has been 
reasonably well established. 7n The results of a 
multicenter randomized comparison of PTA alone 
versus PTA plus stent in iliac lesions has demon- 
strated :conclusively that iliac stent implantation 
results in a significantly higher patency rate at 4 and 
5 years, with low incidence of procedure failures and 
compfications. 7'sThe role of arterial stenting in the 
femoral and popliteat arteries remains controversial. 
Previous reports of femoral stent experience have 
tended to report only early results or have been based 
on poorly defined criteria for the extent of disease and 
determination f outcome. Reproducible standards 
of reporting, as defined in the policy statements of the 
Ad Hoc Subcommittees of the Society for Vascular 
Surgery/International Society for Cardiovascular 
Surgery 12q4 and the Standards of Practice Committee 
of the Society of Cardiovascular nd Interventional 
Radiology, a5 for reports dealing with lower extremity 
ischemia nd for lower extremity endovascular p o- 
cedures, have rarely been applied. 
Initial clinical investigations ofstents in the fem- 
oropopliteal arteries were complicated by a high 
incidence of acute thrombosis, ~6 and because many of 
these procedures were being performed by cardiolo- 
gists, the adoption of strict anticoagulation protocols 
similar to those already being applied to coronary 
angioplasty ensued. These commonly involved intra- 
procedural anticoagulation with systemic heparin, 
continued intravenously for at least 72 hours until 
long-term anticoagulation with warfarin (Couma- 
din) had been established. Coumadin was then used 
for 1 to 3 months with the aim of reducing the 
incidence of early thrombosis of the stent. This had 
the effect of prolonging hospitalization a d was a far 
more complex treatment than PTA alone. 
The purpose of this study was to determine the 
early results and intermediate-term outcome of 
femoropopliteal stents implanted percutaneously, 
without adjunctive long-term anticoagulation (as has 
been the practice for stenting of the iliac arteries and 
aorta in our vascular unit since 1989) and to repol~c 
these results in a format conforming to the above 
criteria. This report presents these preliminary data 
and does not specifically address whether stents 
necessarily improved results over PTA without 
stents. 
PATIENTS AND MATERIAL 
Subjects 
During a 3-year interval (June 1990 to May 
1993), more than 250 patients underwent percuta- 
neous femoropopliteal angioplasty, and, of these, a 
subset of 32 patients had stents inserted in the 
superficial femoral artery (SFA) (n = 22) or pop- 
liteal artery (n = 10). There were 23 men and nine 
women, with a mean age of 65 (range 48 to 79 years). 
All patients were admitted to the vascular surgery 
service after being initially assessed by clinical criteria, 
noninvasive testing (including resting and exercise 
ankle-brachial systolic pressure indexes [ABI] and 
color-flow duplex scanning), and angiography. Re- 
sponse to medical treatment (risk factor stabilization, 
cessation of smoking, walking exercise) was an 
essential component of patient assessment for inter- 
vention. Informed consent was obtained from each 
patient. 
The indications for intravascular stenrs were 
Group I, recurrent stenosis after prior angioplasty 
(n = 13); Group II, suboptimal result immediately 
after angioplasty of occlusions (n = 12) or calcified 
stenotic lesions (n = 2); and Group HI, PTA-induced 
thrombosis or dissection (n = 5). Stents were not 
used as primary therapy in this series. The target 
lesions were stenotic in 17 cases and occlusive in 15 
cases. The lesions were located in the proximal SFA 
(n = 3), mid SFA (n = 4), distal SFA (n = 15), 
proximal popliteal (n = 5), and distal popliteal artery 
(n = 5). The length of stenotic lesions ranged from 
1 cm to 8 cm (mean of 2.7 cm). The length of 
occlusions varied from I cm to 21 cm with a mean of 
4.8 cm. The length of occlusion was less than 3 cm 
in seven cases, 3 to 5 cm in five cases, 5 to 10 cm in 
two cases, and greater than 10 cm in one case. 
These patients were stratified into clinical catego- 
ries of chronic limb ischemia on the basis of the 
objective criteria recommended by the Ad Hoc 
Committee on Reporting Standards, The Society for 
Vascular Surgery/International Society for Cardio- 
vascular Surgery, North American Chapter. 12-I4 
Thirty patients had grade I chronic limb ischemia, 
whereas only two had grade II. These comprised 5
patients in category 1 (mild claudication), 13 patients 
in category 2 (moderate claudication), 12 patients in 
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category 3 (severe claudication), and 2 patients in 
category 5 (minor tissue loss/nonhealing ulcer). The 
resting ABI measured before stent implantation 
ranged from 0.25 to 0.90, with a mean and median 
ABI of 0.63 and 0.65, respectively. A resting ABI less 
than 0.50 was present in eight cases, 0.51 to 0.75 in 
16 cases, and greater than 0.75 in eight cases. 
The distal runoff was categorized, in accordance 
with the published criteria for endovascular p oce- 
dures, 14 as good (i.e., with two or three arteries 
patent o the ankle) in 17 cases and poor (none or one 
artery patent o the ankle) in 15 cases. 
Technique of angioplasty and stent implantation 
Percutaneous angioplasty was performed in the 
operating room in 10 patients and in the interven- 
tional radiology suite in 22 patients. All stent 
procedures were performed by one of three personnel 
among the authors (R. C. W., G. H. W., or J. M.). 
Percutaneous antegrade access to the ipsilateral 
common femoral artery was gained by the Seldinger 
technique.17 Fluoroscopic monitoring was used in all 
cases, with adjunctive imaging by angioscopy (n = 
14) and intravascular ultrasonography (IVUS) 
(n = 5) in selected cases. Balloon dilation PTA 
preceded stent implantation i all cases. In patients in 
whom the indication for stent was elective (recurrent 
stenosis after prior PTA), an arterial sheath (7F to 9F 
diameter) was inserted over a guide wire at the start 
of the procedure. When the indication for stent 
insertion was for salvage of PTA complications or 
poor result, a sheath exchange usually was required, 
replacing the smaller caliber sheath used for PTA 
with a larger diameter sheath suitable for passage of 
the stent. 
In occluded arteries, the lesion was initially 
crossed by guide wire and then dilated by angio- 
plasty balloon. Adjunctive laser recanalization was 
used in eight patients, performed with a 2.5 mm 
hot-tip laser probe over the guide wire and with 14 
to 17 W energy from an Nd:YAG laser energy 
source. In these patients, the indication for stent use 
was poor result of the recanalization process, as 
determined by completion angiography, angios- 
copy, or IVUS. Passage of a guide wire through 
the lesion was not possible in only one case; in this 
instance a laser probe was used to create an initial 
channel through a calcific lesion, and all further 
manipulations were then performed over the guide 
wire. 
The criteria used to judge the results of the 
recanalization process after PTA were determined by 
completion angiography, confirmed by angioscopy 
or IVUS when these later modalities were used. 
Poor outcome was defined as (1) immediate arterial 
closure because of dissection, intimai flap, or throm- 
bus, or (2) residual stenosis of greater than 50% 
lumen diameter, involving an arterial segment of 
several centimeters orgreater length, especially when 
there was evidence of extensive debris within the 
lumen and deterioration i  distal perfusion of the 
limb. 
Medication regimen 
All patients were given 5000 units heparin 
administered systemically after insertion of the 
arterial sheath. Monitoring of the anticoagula- 
tion status was not used. The sheath was removed 
at the conclusion of the procedure, and manual 
pressure was applied over the puncture site for 
as long as was necessary to achieve hemostasis 
(approximately 15 minutes). A pressure dressing 
was then applied. Patients were discharged from 
hospital the following day with instructions to 
take 150 mg aspirin daily. No other anticoagu- 
lants were used, and no patients received oral 
Coumadin. 
Stents 
A total of 34 stents were implanted in the 32 
patients (one stent in 30 cases and two stents in 
two patients). These consisted of 24 balloon- 
expandable Strecker stents (Meditech, Boston Sci- 
entific, Watertown, Mass.) and 10 self-expanding 
Wall stents (Schneider Co., Switzerland). These 
stents were inserted in 22 SFA and 10 popliteal 
arteries. Because there were no available data to 
support a superiority of one design over others, the 
type of stent used in each case was based on the 
length of lesion, personal preference of the physician 
involved, and availability of stock. Palrnaz femoral 
stents (Johnson & Johnson, New Brunswick, N.J.) 
were not available to use until the time of the 
completion of this study. Balloon-expandable st nts 
were inflated to the diameter of adjacent, relatively 
normal vessel, in general with the aim of embedding 
the stent into the arterial wall and avoiding un- 
derexpansion. Purposeful overexpansion, as advo- 
cated by some, was not used. Self-expanding stents 
were assessed after initial deployment and adjunctive 
balloon dilation was used if it was judged that the 
stent was underexpanded or that the original ath- 
erosclerotic lesion was deforming part of the stent. 
These judgments were made according to the fluo- 
roscopic image or by the angioscopic or IVUS 
assessment, when performed. 
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Follow-up and statistical analysis 
Completion angiograms were obtained for each 
procedure, and all patients were monitored initially 
by duplex scarming and ABI after return to the 
vascular surgery ward, within 24 hours of stent 
implantation. Subsequent follow-up was by clinical 
examination at the vascular surgeon's office and also 
by noninvasive testing (ABI and duplex scanning) 
within 1 month of hospital discharge and thereafter 
at 3- to 6-month intervals. Degrees of stenosis were 
calculated from duplex scanning according to the 
criteria of Cossman et al. 18 Patency of the treated 
artery was strictly defined as demonstrably patent at 
duplex scan imaging, with maintenance of the 
improved limb pressure index. "Restenosis" was 
defined as demonstration of stenosis greater than 
50% within the stent, at the stent/artery boundary or 
within the adjacent segment of artery. Stents with 
objective vidence of restenosis, recurrence of symp- 
toms, and deterioration of the previously attained 
improvement in ABI were defined as "failing" stems. 
Cumulative patency rates were calculated by the 
method of tile-table analysis. 12 Primary, patency, 
assisted primary patency, la and secondary patency 
rates were calculated. Primary patency was defined as 
the patency after initial stenting. Assisted primary 
patency was the patency achieved after additional 
interventions on patent but "failing" stents (symp- 
tomatic stenosis within the stent, confirmed by 
angiography and managed by PTA). Secondary 
patency was the patency achieved after a complemen- 
tary interventional procedure on failed or occluded 
stents (PTA or thrombolysis). 
The reporting interval for patients lost to follow- 
up, or those who died with patent arteries, stopped 
at their last follow-up visit. Patients who had had 
development of occlusion or stenosis ince their last 
examination were treated as having failure halfway 
between the two examinations. Differences in pa- 
tency were calculated for subgroups according to 
indication for stent use, site of implantation, status of 
runoff, type of stent used, and stenosis versus 
occlusion. 
RESULTS 
Successful stem implantation was achieved in 31 
of the 32 patients (96.9%). The one implantation 
failure was in a 3 cm length occlusion of the distal 
SFA and was due to a faulty delivering system of a 
balloon-expandable st nt, resulting in rupture of the 
balloon, which then became nmeshed with the stent 
struts, causing inadvertent removal of the stent. 
(Interestingly, this complication also resulted in a 
localized endarterectomy or atherectomy of the 
atherosclerotic tissue attached to the stent, and the 
artery remained patent for 5 months. This "hemo- 
dynamic success" could thus be alternatively classified 
as a successful procedure if the reporting uidelines 
were strictly applied.) 
There were two cases of procedure-associated 
complications; in each of these, acute thrombosis 
within the stent occurred at 24 and 48 hours after the 
procedures, respectively, resulting in an acceptable 
frequency of 6.3% for acute thrombotic occlusion in 
this series. The first occurred in a 3 cm occluded 
segment of distal SFA that was managed with a 
balloon-expandable st nt after suboptimal recanali- 
zation by laser-assisted angioplast T. The stent was 
successfully salvaged by thrombolysis, with intraar- 
terial infusion of urokinase, but symptomatic reste- 
nosis subsequently occurred within the stent at an 
interval of 13 months. The second occlusion occurred 
at 48 hours after stent placement in a heavily calcified 
midpopliteal stenotic lesion. Attempts to salvage the 
stent with urokinase infusion failed, and a femo- 
ropopliteal bypass was later performed. There were 
no other instances ofstent hrombosis within 30 days 
of the procedure, and the 30-day operative mortality 
rate was 0%. 
Bruising hematoma t the puncture site was 
almost always present but was not severe nough to 
warrant surgical intervention or other specific treat- 
ment in any patient. There was no incidence of 
hemorrhage, vessel perforation, acute leg ischemia, 
distal microembolism, false aneurysm, or significant 
groin hematoma. No patient required admission to 
the intensive care unit, and no urgent surgery was 
required. 
The follow-up ranged from 3 to 33 months, with 
a mean and median follow-up of 18.5 and 17 months, 
rcspectivcly. During this period, two patients died of 
ischemic heart disease, and one died of progressive 
heart failure, all with their stents till patent at 4, 5, 
and 7 months, respectively, at last follow-up. One 
patient returned to his original country of residence 
on a South Pacific island and thus was lost to 
follow-up. 
Stent occlusion occurred in four patients during 
follow-up (in addition to the two acute occlusions 
mentioned above; thc overall occlusion rate is 6 of 31 
[19.4%]) at 2, 2, 10, and 18 months. All four late 
stent occlusions were in the SFA, and one was 
successfully reopened by urokinase infusion. When 
analyzed for site, stent occlusion (acute or chronic) 
has occurred in 1 of 10 (10%) within the popliteal 
artery compared with 5 of 22 (22.7%) within the 
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Table I. Vascular stents in femoral and popliteai arteries (results) 
Follow-up Restenosis rate Occlusion rate 
Authors Year (mos) (%) (%) 
Rousseau et al. 26 1989 6 35 20 
Gf inther  et al. 2s 1989 7.8 30 - 
Sapoval  et al. 16 1992 17.6 - 41 
Zol l i foker et al. 24 1991 20 - 45 
Strecker et al. 41 1993 12 18 - 
Henry  et a l# 2 1993 6 20  12 
Vorwerk  and G/ Jnther  1I 1990 7.8 26  - 
SFA. This difference did not reach statistical signifi- 
cance. 
Stenosis within the stent (>50% of luminal 
diameter) was detected inseven patients between 4 to 
15 months after the procedures (mean 9.5 months). 
These included the two patients who had previously 
undergone thrombolysis of occluded stents. Four of 
the seven patients in this group remain clinically 
symptom free, with no significant change: in their 
ABI despite the duplex ultrasonography findings; 
hence, no further interventions were performed. The 
other three patients had symptoms requiring further 
PTA within the stents. These stents have remained 
patent after PTA up to their most recent follow-up. 
Overall, stent occlusion occurred in I of 13 
restenoses (group I), 4 of 14 suboptimal angioplas- 
ties (group II), and 1 of 5 PTA salvages (group III). 
Restenosis greater than 50% (symptomatic plus 
asymptomatic) occurred in 2 of 13 patients, 3 of 14 
patients, and 2 of 5 patients, respectively, for the 
same groups. These differences do not have statistical 
significance. 
The mean ABI improved from 0.63 to 0.86 at 3 
to 6 months. The cumulative primary patency rate at 
12 and 18 months in this series was 75% (Table II), 
the assisted primary patency rates at 12 and 18 
months, respectively, were 82% and 78% (Table III), 
and the secondary patency rate was 89% at 12 and 18 
months (Table IV). The standard error of these 
figures exceeded 10% after the 18-month follow-up 
interval (Fig. 1). This is defined as intermediate-term 
follow-up by the Ad-Hoc Committee guiddinesJ 4 
There were no significant differences in the rates 
of stent occlusion or restenosis among the following 
groups: (1) indication for insertion restenosis after 
prior PTA versus improvement or salvage of PTA 
result, (2) good runoffversus poor runoff, (3) target 
lesion occlusion versus tenosis, (4) Wallstent versus 
Strecker stent. These findings reflect the low numbers 
of patients in this study and the relatively short 
follow-up at this stage. 
DISCUSSION 
We have concluded from this experience that 
long-term anticoagulation is not necessary for stent- 
ing of the femoral or popliteal arteries (when single 
stents are used for short length lesions, in the way 
described in this study). This contradicts he advice 
given by several previous reports of stent use in the 
infrainguinal rteries, wherein a relatively high inci- 
dence of early stent thrombosis was encountered, 
leading to adoption of strict anticoagulation regi- 
mens. 1°'16J9 Avoiding a rigorous preprocedure and 
postprocedure anticoagulation protocol allows early 
discharge of the patient from the hospital and 
maintains the concept of less-invasive therapy. Even 
if future prospective, randomized studies how that 
patency rates can be improved by use of Coumadin, 
it is doubtful whether the added risks and inconve- 
nience for the patient (increased hospital stay, fre- 
quent monitoring of blood coagulation tests, etc.) 
would be warranted in this group of patients with 
relatively early arterial disease. These conclusions 
cannot be extrapolated to stent use in recanalized 
long occlusions ( > 10 cm) or for multiple stent use 
because these situations were not included in this 
study. There is evidence that use of multiple stents 
for recanalization of long occlusions is ineffective; 
Do et al.19 carried out a comparative study of 
self-expandable stents versus balloon angioplasty 
alone in femoropopliteal artery occlusions of 3 cm 
length or longer (mean length 8.6 cm) and reported 
similar patency rates (60% to 65%) for each treat- 
ment modality at 12 months. 
The use of long-term anticoagulation protocols 
after angioplasty is associated with a higher incidence 
of bleeding complications; this is particularly well 
documented in coronary artery angioplasty. 6 In this 
study, there was no incidence of hemorrhage, severe 
hematoma, orfalse aneurysm formation at the arterial 
puncture site, whereas Sapoval et al.16 reported 
hemorrhagic complications in 10 of 22 patients who 
had Wallstents implanted in the femoropopliteal 
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Table II. Primary patency: life-table data for initial stent placement without an 
additional procedure 
No. of stents withdrawn from study 
Interval No. of stents at No. of Interval 
(too.) start of interval failed stents Duration Lost to follow-up Death patency 
Cumu&uve 
pa~n 0, SE 
(%) (%) 
0-1 31 2 0 1 0 0.93 100 0 
1-6 28 3 2 0 2 0.89 93 4.7 
6-12 21 2 3 0 1 0.90 83 7.5 
12-18 15 0 5 0 0 1.00 75 9.7 
18-24 10 1 4 0 0 0.86 75 11.9 
24-30 5 0 4 0 0 !.00 64 17.I 
30-36 1 0 0 0 0 1.00 64 38 
Table III. Assisted primary patency: life-table data for initial stent placement with an additional 
intervention on "failing stents" 
No. of stents withdrawn from study Cumulative 
Interval No. of stents at No. of Interval patency SE 
(too.) start of interval failed stents Duration Lost to follow-up Death pateney (%) (%) 
0-1 31 2 0 1 0 0.93 100 0 
1-6 28 2 2 0 2 0.92 93 4.7 
6-12 22 1 3 0 1 0.95 86 6,9 
12-18 17 0 7 0 0 0.95 82 8.4 
18-24 10 I 4 0 0 0.88 78 11.6 
24-30 5 0 4 0 0 1.00 68 17.2 
30-36 1 0 0 0 0 1.00 68 38.5 
arteries, with maintained anticoagulation. Our expe- 
rience suggests that long-term, oral anticoagulation 
may be reserved for patients who have early throm- 
botic occlusion of the stent, which can be salvaged by 
secondary interventions, including thrombolysis. A 
recent report has also suggested that good results can 
also be obtained in stenting coronary arteries without 
long-term anticoagulation if high pressure dilation is 
used to expand the stented atherosclerotic lesion 
fully, g0 
It should be emphasized that the results obtained 
in this series may differ from other published series 
because of our tendency toward selective use ofstents 
in patients with the following characteristics: (1) 
early stage of disease (claudication i  all but two 
cases), (2) short length of lesions, and (3) avoidance 
of multiple, overlapping stents. In general, we have 
followed a policy of not attempting percutaneous 
recanalization in vessels with lesions of length greater 
than 10 cm because of the poor results obtained 
previously in such cases by either balloon PTA 2,21 or 
laser-assisted PTA. 22,23 Initial assessment of patients 
by duplex scanning led to exclusion of patients 
considered unsuitable for endovascular p ocedures 
before reaching the angiography suite. Cost/benefit 
constraints have been a significant limitation to the 
number of stents used. 
In previous tudies where patient selection was 
less stringent and attempts were made to treat longer 
lengths of occluded artery, results were unfavorable. 
For example, in the femoropopliteal rtery group 
reported by Zollikofer et al,, 24 Wallstent devices were 
used in long-segment (mean, 13.5 cm) occlusions, 
with inadequate r sponse to percutaneous recanali- 
zation in 15 patients. In these lesions, of 11 patients 
available for follow-up, only six had patent stents at 
7 to 26 months (mean 20 months). Four of these six 
patients required one to three secondary interven- 
tions. These authors concluded that sclf-expanding 
endoprostheses are of great value in complex lilac 
artery lesions where simple balloon dilation is insuf- 
ficient but that stent placement for long femoral 
artery lesions should be performed with utmost 
reserve and the extent ofstent placement should be as 
short as possible. After similar experience, Gtinther et 
al.2s concluded that the low patency rate in femoral 
arteries restricts stent implantation to a selected 
subset of lesions that are not amenable to balloon 
angioplasw alone. 
Rousseau et al.26 reported that restenosis (defined 
as more than 50% si@e diameter stenosis in the 
stented segment) occurred in 30% of 45 femo- 
ropopliteal stent sites with at least 6 months' 
follow-up after stenting, despite use of Coumadin for 
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Table IV. Secondary patency: life-table data for initial stent placement with 
additional interventions 
No. of stents withdrawn from study 
Interval No. of 6tents No. of 
(too.) at start of interval failed stents Duration Lost to follow-up Death 
Cumulative 
Interval patency SE 
patency (%) (%) 
0-1 31 1 0 1 0 
1-6 29 1 2 0 2 
6-12 24 1 3 0 1 
12-18 19 0 7 0 0 
18-24 12 1 5 0 0 
24-30 6 0 5 0 0 
30-36 1 0 0 0 0 
0.97 100 0 
0.96 93 3.1 
0.95 93 5.0 
1.00 89 6.8 
0.90 89 8.5 
1.00 80 14.6 
1.00 80 35.8 
2 months to prevent acute thrombosis and deposition 
of thrombus on the stent. Restenotic lesions were 
treated by atherectomy, and the pathologic speci- 
mens showed that intimal proliferation was the cause 
of restenosis. 
The long-term benefit of stent use in the femoral 
artery therefore remains unproven at present, al- 
though many investigators confirm that stents are 
very valuable in the management ofdissections of this 
vessel that occur after interventions, with acceptable 
patency resulting in this salvage situation. So far, 
there is no clear evidence that stents reduce the 
restenosis rate in the superficial femoral or popliteal 
artery position; stents themselves do not prevent 
intimal hyperplasia nd fibroblast overgrowth. This 
study has not specifically addressed the question of 
whether stents can improve the results of repeat PTA 
for recurrent stenotic lesions of the femoral artery; a 
randomized study comparing PTA with PTA plus 
stenting seems warranted in this situation. Restenosis 
within the stent may become asignificant problem in 
those patients with severe preexisting vascular dis- 
ease, and long-term results depend on the degree, 
frequency, and progression of intimal hyperplasia 
narrowing the vessel or stent lumen. 
This study confirms the findings of others that 
restenosis after angioplasty is not eliminated by stent 
use. Restenosis was detected by duplex scanning at 
this relatively early interval in seven of 25 patent 
stents (28%) implanted to date, although only three 
(12%) of these are defined as failed procedures by the 
Ad Hoc Subcommittee guidelines. The significance 
of asymptomatic stenosis within the stent remains 
uncertain at this stage, although it seems likely that 
these will progress or occlude. The overall failure rate 
(occlusion or symptomatic restenosis) by life-table 
analysis was 25% at 18 months. Other studies have 
shown similar or higher rates of restenosis and 
occlusion and evidence of a process of neointimal 
hyperplasia within femoral stents has been provided 
by histologic analysis of atherectomy specimens 
extracted from restenotic lesions. 1°,19 
It has been observed that some patients seem 
inherently prone to restenosis after PTA or after stent 
implantation, whereas others heal with a relatively 
normal neointimal fining and vessel wall. Differences 
in response between patients may be due to differ- 
ences in vascular tissue, differences in flow, differ- 
ences in lumen diameter, and numerous other factors, 
including levels of lipoprotein a. 27'28 Angioscopic 
examinations of the stent lumen at several months 
have often shown smooth covering of the stent by 
normal neointima in our own experience and in the 
experience of others. 29 
Increased rates of restenosis in femoral and 
popliteal arteries may be due to decreased flow. 
Significant differences in neointimal healing were 
found between normally perfused stents and stents 
with artificially reduced flow in dogs, 3° with the 
buildup of neointimal height being up to 200% 
greater in flow-restricted dtents. It is also considered 
that poor distal flow encourages intimal hyperplasia 
and therefore recurrences) 1 
The inferior resuks in SFA and distal arteries (in 
comparison to the iliac arteries) may also be associ- 
ated with the size of the stent relative to the arterial 
diameter. In an early report, Palmaz 32 pointed out 
that the usual deposition of a layer of surface 
thrombus on an arterial stent will tend to reduce the 
lumen more markedly in small arteries and therefore 
decrease flow. He concluded that the metal surface in 
small-caliber stents must be kept as small as possible 
by improvements in the mesh design. Duprat et al.33 
found that vessels of diameter 3 mm or less had 
occlusion rates of 50% after stent implantation in 
undiseased animal arteries. The diameter of the stent 
relative to the artery was shown to be an important 
factor. Sapoval et al.~6 reported that stented human 
SFAs of diameter less than 5 mm were more likely to 
reocclude than arteries 5 mm or greater. 
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Fig. 1. Graphic representation f life-table data for initial stent placement without additional 
procedure. Primary. patency rate was 75% at 18 months. Data beyond 18-month follow-up 
interval have standard error greater than 10% and are therefore shown as dotted line. 
It has been proposed that lining the stent wall 
with a coating of prosthetic material may act as a 
physical barrier to the ingrowth of neointimal 
hyperplasia through the stent mesh and thereby 
reduce the problem of restenosis. 3<3s Initial applica- 
tion of such coated stents or stent-graft combinations 
has been in the endoluminal management of aneu- 
rysmal disease a6,37 or trauma, 38 and initial clinical 
experience of percutaneously placed stent-grafts for 
recanalization foccluded peripheral rteries has now 
been reported. 39 
During this study, we had concerns that stents 
placed in the femoral and distal vasculature may be 
compromised by the potential for external compres- 
sion of the stent, causing obliteration and thrombosis 
of the lumen, or that movements atthe hip and knee 
joints may kink the stent wall. It has been demon- 
strated, by angiographic studies of the arteries 
adjoining the knee, that extensive kinking and 
stenoses of the popliteal artery and less frequently of 
the distal femoral artery occur during flexion of the 
knee joint. 4° These factors were considered to favor 
application of flexible stents in these sites, but this 
matter remains controversial. Data available so far 
from this study and from others do not indicate that 
stent compression or bending have been a significant 
clinical problem, but it is possible that these factors 
may also contribute to increased evelopment of 
neointimal hyperplasia. 
It is interesting to note the relatively favorable 
results obtained in the popliteal artery at this interval 
of follow-up. Only one of 10 popliteal stents has 
occluded; this may reflect selection of more favorable 
lesions at this site but suggests that kinking of the 
stent by flexion of the knee is not a significant clinical 
problem. We have also tended to select patients with 
lesions less than 10 cm in length. This partly explains 
the better esults obtained in comparison to several 
other reports, which included a high proportion of 
patients with long segmental occlusions of the SFA 
and popliteal artery, which were treated by multiple 
stents in many cases. 
The incidence of procedure-associated complica- 
tions in this series is relatively low, with 2 instances 
of acute thrombosis (6%) and one failed implanta- 
tion. In addition, there was no incidence of false 
aneurysm, acute leg ischemia from distal microem- 
bolism, vessel perforation, or significant groin he- 
matoma. These factors demonstrate hat stenting the 
femoropopliteal rteries can be performed safely 
when good patient selection is applied. 
We conclude that vascular stents can be implanted 
into the femoropopliteal arteries with few complica- 
tions and acceptable intermediate-term patency (for 
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this group of salvage situations and recurrent le- 
sions), without the need for long-term anticoagula- 
tion. Restenosis occurs in a high proportion of cases, 
although this does not always produce recurrent 
symptoms. The main value of stenting at this site 
appears to be in salvaging acute complications of 
PTA, or to correct suboptimal result after recanali- 
zation of short-length arterial occlusions. Longer 
follow-up, greater numbers of patients, and random- 
ized studies will be required to define further the role 
of femoropopliteal stenting, particularly in the man- 
agement of restenosis after PTA. The possibility that 
coated stents or endoluminal grafts may reduce the 
incidence of restenosis hould be investigated. 
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DISCUSSION 
Dr. K. Wayne Johnston (Toronto, Ontario, Canada). 
The authors are to be commended for following the 
suggested reporting standards. The manuscript clearly 
shows the very early results of the treatment of patients 
with claudication by use of stents. I have several criticisms 
of this series, some of which the authors have clearly 
acknowledged in the manuscript. First of all, a potpourri of 
lesions were treated in this study. For example, as pointed 
out, two different types of stents were used, and eight 
occlusions were treated by laser before stent insertion. This 
makes analysis and interpretation of the results extremely 
difficult. 
A major conclusion of this study is that long-term 
anticoagulation is not necessary, but note that no similar 
group of patients is provided for comparison. This study 
therefore does not provide data to determine whether 
anticoagulants are justified. 
The cases in this series do not appear to be the most 
challenging that interventional radiologists or surgeons 
face. Half the lesions were stenotic and half were occlu- 
sions, but all were relatively short. Furthermore, from a 
clinical point of view, 18 of the 32 patients had only mild 
or moderate clandication. 
The 32 patients having stents represented a small subset 
of the 200 patients having PTA of the femoral popliteal 
segment in the Sydney group over a 21/2 - to 3-year period. 
With this number of patients, the authors had the 
opportunity to randomize patients and to answer impor- 
tant questions related to the use ofstents. For example, do 
stents have a role in the treatment of recurrent stenosis or 
is a simple repeat PTA an alternative? Repeat stenosis was 
an indication in 41%. Our experience many years ago with 
balloon angioplasty was that repeat PTA was almost as 
effective as the initial PTA. What is the meaning of the 
statement that a patient has had a suboptimal PTA, and 
therefore hove does one determine whether improved 
long-term results are obtained in this group of patients? For 
the treatment of calcified lesions, do stents actually provide 
improved patency? Finally, because stenosis was not 
eliminated by stents, what is the basic rationale for use of 
a stent? 
Dr. Geoffrey H. White. I am in agreement with many 
of the criticisms that Dr. Johnson has raised. The selection 
of short length, relatively early atherosclerotic lesions for 
arterial stenting in this series was largely brought about by 
our practice of limiting angioplasty to such lesions- 
because stents were used in a subset of patients undergoing 
angioplasty of various types, this selection was unavoidable. 
There is ample evidence from other studies, and from our 
own previous experience, that percutaneous recanalization 
of long lesions carries an unsatisfactot T long-term patency 
rate and some of the publications cited demonstrate hat 
stenting long segments (or use of multiple stents) does not 
greatly improve the results of angioplasty in the femo- 
ropopliteal position. Other investigators have taken the 
view that use of long-term anticoagulation may be the way 
to improve these results, whereas we had the impression 
that selection of shorter lesions and limiting stent use to 
salvage situations may be more important. 
This was a retrospective study, and there was no 
randomization fpatients to different treatment groups, so 
many of the specific questions that Dr. Johnson has raised 
cannot be answered by these data. Nevertheless, I would 
like to take issue with Dr. Johnson's assertation that we 
have not really shown that anticoagulation is unnecessa U.
Certainly a comparative study would also be helpful, but 
the point of Coumadin use in other studies has been to 
reduce the incidence of early stent hrombosis, and we feel 
that this study demonstrates that this complication can be 
avoided more preferably by good patient selection and by 
limiting the number of stents implanted. By avoiding use 
of Coumadin, we can reduce hospital stay, bleeding 
complications, and the necessity for multiple blood tests in 
the follow-up period. 
The definition of "suboptimal PTA result" is dealt 
with in more detail in the text of the study than was 
possible to present. There must of course be a subiective 
element in this judgment, dependent on the experience 
of the surgeon or radiologist doing the procedure and 
the imaging modality being used. Some degree of dis- 
section of the plaque and arterial wall probably occurs 
in most PTA procedures, and ha many cases it was 
determined that the outcome of the angioplasty procedure 
alone was "suboptimal" by a combination of the anglo- 
graphic appearance and the findings at angioscopy or 
IVUS, usually when the residual stenosis or debris within 
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the lumen was considered to be significantly more than 
50% despite multiple dilations of the lesion. 
The question about what is the basic rationale or true 
role of stents in the femoropopliteal rteries cannot be 
specifically answered by this study, but the data do show 
that when single stents are used for salvage of acute 
ischemia or poor recanalization utcome from PTA, then 
a good early result and reasonable intermediate patency can 
be achieved, without having to commit the patient to 
long-term anticoagulation. This suggests that stenting of 
the femoral artery should not be sweepingly rejected and 
that randomized studies of stent use in the management of
recurrent lesions and total occlusions are warranted. 
My opinion is that the current range of stents will 
continue to have a role in the salvage of acute closure of the 
femoropopliteal artery occurring as a complication of PTA, 
but that covered stents or endoluminal grafts will eventu- 
ally be preferred for recanalization of longer lesions and 
total occlusions. 
Dr. James M. Seeger (Gainesville, Fla.). It's somewhat 
surprising that your immediate thrombosis rate was as low 
as it is, and certainly our results are in contradiction to 
some previous reports, particularly those out of France. In 
addition, in our work in the laboratory, stainless steel, from 
which these stents are made, is one of the most thrombo- 
genic materials that we have examined. 
Can you explain why your thrombosis rate was as low 
as it is? Did it have to do with the fact that you, in almost 
all patients, only used one stent as opposed to multiple 
stents, which other investigators have reported? 
Second, your report suggests that stents may be safe 
and therefore could be of potential value in patients with 
superficial femoral artery disease. Can you compare the 
results of this study with results of balloon angioplasty 
alone that you did in other patients not reported here? Did 
you show any significant benefit o use of stents in this 
location compared with just plain balloon angioplasty 
alone? 
Dr. White. When we first started using stents in the 
femoral artery, we were very concerned that the metal 
would be thrombogenic and that the stent would act as a 
foreign body and would entice an intense proliferative 
reaction. As a result, we started fairly cautiously, and I think 
the selection of patients reflects that. Some of the other 
studies that Dr. Seeger eferred to were fairly enthusiastic 
attempts to recannalize long occlusions, that is, the total 
length of the superficial femoral artery. This experience was 
necessary, but I think the outcome was fairly predictable. If  
you try to recannalize something that is 25 cm long and you 
put five or six stents in, it's not difficult to see why there's 
going to be a higher incidence of thrombosis compared 
with the use of a stent in a stenotic lesion where the stent 
is only 3 or 4 cm long, and there's better flow through the 
stent. 
Dr. Samuel S. Ahn (Los Angeles, Calif.). I think we 
have to be very careful about what conclusions we draw 
from the data presented. As far as I can see-and  I agree 
with Dr. Johnston's criticism of the study-this  study 
represents more anecdotal evidence of some potentially 
important benefits of stents; that is, stents may be an 
important bail-out device for acutely failed or failing 
balloon angioplasty procedures. I don't think the study has 
answered the question about whether stents prevent 
restenosis and intimal hyperplasia, or whether stents are 
thrombogenic. 
With favorable short occlusive or stenotic lesions, the 
long-term results with stents are not any worse than with 
balloon angioplasty alone, if you can salvage abad result o 
be a good angiographic result with the use of stents. 
In this favorable group of patients, one can achieve an 
18- to 24-month 75% patency rate with or without stents. 
Did you note any external compression of the stents as 
reported by other authors? Second, did yon look at your 
own institution's PTA data about what your results are 
without stents at 18 months for comparable l sions? 
Dr. White. I don't agree that this experience can be 
dismissed as anecdotal. It has already been acknowledged 
that a range of lesions have been treated and that there is 
no control group, but the indications for intervention and 
patient characteristics have been documented carefully as 
stipulated by the Ad Hoc Committee reporting standards 
and the follow-up by duplex scanning has been fairly 
thorough. 
In a way, this study can be regarded more as a phase one 
or pilot study documenting the behavior of arterial stents 
in the intermediate rm and the response of the arterial 
wall to this metallic foreign body. Stents do not prevent 
restenosis. That's obvious from this and all the other 
studies. But restenosis only develops in a proportion of the 
patients and not in others. It is interesting to follow the 
progress of this response on successive duplex scans and to 
observe that, in some patients, a smooth type of asymp- 
tomatic lesion develops, somewhat analogous to the 
restenotic lesion that may occur after endarterectomy of the 
carotid artery. 
On the other hand, in some patients a completely 
occluded artery has been recanalized by PTA and then the 
geometry of the damaged arterial segment opened out by 
the stent with a result of a nicely smooth, widely patent 
artery being maintained at an interval of several years. The 
reasons behind this vastly variable outcome should be 
studied extensively. 
We have not observed external compression of the 
stent, and reports of this phenomenon have been surpris- 
ingly sparse. I was fascinated to find that, of the 10 stents 
that we have implanted into the popliteal artery, where we 
expected that flexion of the knee could create a major 
compression deformity to the stent, to date only one of 
these has had significant stenosis or occlusion. Most of the 
stent failures have actually been in the adductor canal 
region of the superficial femoral artery and not in the more 
exposed segments where external compression might be 
expected to be a cause of failure. 
Dr. Michael D. Dake (Stanford, Calif.). What consti- 
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tutes an optimal or suboptimal balloon angioplasty or 
atherectomy? I was wondering if you thought here was a 
role for intraprocedural peak systolic velocities measured at 
the site of intervention as a means of endpoint assessment. 
Dr. White. Experience is necessary for interpretation 
of the significance of findings of angioscopy and intravas- 
cular ultrasonography. With this experience, you come to 
recognize that lesser degrees of dissections and flaps are 
typically seen on these imaging modalities after balloon 
dilation. Only the more extreme postintervention dissec- 
tion lesions and residual stenoses were regarded as subop- 
timal result. Again, it is acknowledged that this was usually 
a subjective judgement, except in situations where total 
occlusion of the artery had occurred. 
Intraprocedural duplex scanning was not readily avail- 
able for these cases and noninvasive imaging typically done 
on the following day. Your suggestion regarding the use of 
immediate Doppler or duplex imaging, with peak systolic 
velocity analysis, is a good concept and should be studied. 
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